INCYTE CORP INCY
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research
Chart by TradingView
6/9
Piotroski F — financial health
7.9
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $5.1B | $1.3B | — | — | $5.2B |
| 2024 | $4.2B | $32.6M | — | — | $3.4B |
| 2023 | $3.7B | $597.6M | — | — | $5.2B |
| 2022 | $3.4B | $340.7M | — | — | $4.4B |
| 2021 | $3.0B | $948.6M | — | — | $3.8B |
| 2020 | $2.7B | -$295.7M | — | — | $2.6B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | director | 2026-06-08 | Grant | 1,642 | — |
| BAKER BROS. ADVISORS LP | director | 2026-06-08 | Grant | 1,642 | — |
| HARRIGAN EDMUND | director | 2026-06-08 | Grant | 1,642 | — |
| Clancy Paul J | director | 2026-06-08 | Grant | 1,642 | — |
| FOUSE JACQUALYN A | director | 2026-06-08 | Grant | 1,642 | — |
| BIENAIME JEAN JACQUES | director | 2026-06-08 | Grant | 1,642 | — |
| High Katherine A | director | 2026-06-08 | Grant | 1,642 | — |
| BRAWLEY OTIS W | director | 2026-06-08 | Grant | 1,642 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.9 (safe)
- Working capital / assets 0.504
- Retained earnings / assets 0.031
- EBIT / assets 0.218
- Equity / liabilities 2.886
Source: SEC EDGAR filings · CIK 0000879169 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.